Spark Therapeutics announced a strategic collaboration to develop Neurochase’s proprietary delivery technology for use with selected gene therapies for rare diseases in CNS. Through this collaboration, Neurochase will bring their deep expertise in direct drug delivery technology to Spark’s leading AAV platform. Neurochase is developing a proprietary drug delivery system and this collaboration enables Spark to develop selected gene therapies for CNS disorders using the Neurochase technology, which aims to improve targeted delivery of AAV gene therapy to neural structures using the method of Convection Enhanced Delivery.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on RHHBY:
- Roche launches COVID-19 PCR test to detect XBB.1.5 Omicron sub-variant
- Roche launches COVID-19 PCR test to detect the fast spreading XBB.1.5 Omicron sub-variant
- TG Therapeutics price target raised to $25 from $16 at Evercore ISI
- Roche says Phase 3 IMbrave050 study of Tecentriq-Avastin met primary endpoint
- [Ad hoc announcement pursuant to Art. 53 LR] Roche’s Tecentriq plus Avastin is the first treatment combination to reduce the risk of cancer returning in people with certain types of early-stage liver cancer in a Phase III trial
